Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 3/2009

01-09-2009 | Original Article

Ancillary p16INK4a adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study

Authors: Chung-Chin Yao, Lai-Fong Kok, Ming-Yung Lee, Po-Hui Wang, Tina S. Wu, Yeu-Sheng Tyan, Ya-Wen Cheng, Mei-Fen Kung, Chih-Ping Han

Published in: Archives of Gynecology and Obstetrics | Issue 3/2009

Login to get access

Abstract

Purpose

Endocervical adenocarcinomas (ECA) and endometrial adenocarcinomas (EMA) are uterine malignancies that have differing biological behavior. The choice of appropriate therapeutic plan depends indeed on the tumor’s site of origin. In this study, we not only compare the individual expression status of five immunomarkers (ER, PR, Vim, CEA, and p16INK4a), but also evaluate whether p16INK4a adds value to the ER/PR/Vim/CEA panel characteristics in distinguishing between primary ECA and EMA.

Methods

A tissue microarray (TMA) was constructed using paraffin-embedded, formalin-fixed tissues from 35 hysterectomy specimens, including 14 ECA and 21 EMA. TMA sections were immunostained with five anti-bodies, by avidin–biotin complex (ABC) method for antigen visualization. The staining intensity and area extent of the immunohistochemical (IHC) reactions were appraised by using the semi-quantitative scoring system.

Results

The four respective markers (ER, PR, Vim, CEA) and their combined panel expressions showed significant (p < 0.05) frequency differences between ECA and EMA tumors. The p16INK4a marker also revealed a significant frequency difference (p < 0.05) between the two sites of origin, but did not demonstrate to have any supplementary value to the 4-marker panel.

Conclusion

According to our data, when there is histomorphological and clinical doubt as to the primary site of origin, we recommend that the conventional 4-marker (ER/PR/Vim/CEA) panel is appropriate. Ancillary p16INK4a-marker testing does not add value to the 4-marker panel in distinguishing between primary ECA and EMA.
Literature
1.
Luran JR (2007) Uterine cancer. Gynecology, Chap. 33, 14th edn. Berek & Novak, Philadelphia, pp 1343–1402
2.
Bidus MA, Elkas JC (2007) Cervical and vagianl cancer. Gynecology, Chap. 34, 14th edn. Berek & Novak, Philadelphia, pp 1343–1402
3.
Dabbs DJ, Sturtz K, Zaino RJ (1996) Distinguishing endometrial from endocervical adenocarcinoma. Hum Pathol 27(2):172–177PubMedCrossRef
4.
Castrillon DH, Lee KR, Nucci MR (2002) Distinction between endometrial, endocervical adenocarcinoma: An immunohistochemical study. Int J Gynecol Pathol 21(1):4–10PubMedCrossRef
5.
McCluggage WG, Sumathi VP, McBride HA, Patterson AA (2002) A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 21(1):11–15PubMedCrossRef
6.
Alkushi A, Irving J, Hsu F, Dupuis B, Liu CL, Rijn M, Gilks CB (2003) Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 442(3):271–277 [Epub 2003 Feb 12]PubMed
7.
Zweig MH, Campbell G (1993) Receiver-Operating Characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39(4):561–577PubMed
8.
9.
Remmele W, Schicketanz KH (1993) Immunohistochemical determination of estrogen, progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 189(8):862–866PubMed
10.
Matos LL, Stabenow E, Tavares MR, Ferraz AR, Capelozzi VL, Pinhal MA (2006) Immunohistochemistry quantification by a digital computer-assisted method compared to semiquantitative analysis. Clinics 61(5):417–424PubMedCrossRef
11.
Kamoi S, AlJuboury MI, Akin MR, Silverberg SG (2002) Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint. Int J Gynecol Pathol 21(3):217–223PubMedCrossRef
12.
Khoury T, Tan D, Wang J, Intengan M, Yang J, Alrawi S, Yan P, Byrd JC (2006) Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinoma. BMC Clin Pathol 6:1PubMedCrossRef
13.
Han CP, Lee MY, Tzeng SL, Yao CC, Wang PH, Cheng YW, Chen SL, Wu TS, Tyan YS, Kok LF (2008) Nuclear Receptor Interaction Protein (NRIP) expression assay using human tissue microarray and immunohistochemistry technology confirming nuclear localization. J Exp Clin Cancer Res 27:25PubMedCrossRef
14.
Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8(11):1323–1327 [Epub 2002 Oct 21]PubMedCrossRef
15.
Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA (2006) Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 19(8):1091–1100 [Epub 2006 Apr 28]PubMed
16.
Cregger M, Berger AJ, Rimm DL (2006) Immunohistochemistry and quantitative analysis of protein expression. Arch Pathol Lab Med 130(7):1026–1030PubMed
17.
18.
Fregonesi PA, Teresa DB, Duarte RA, Neto CB, de Oliveira MR, Soares CP (2003) p16(INK4A) immunohistochemical overexpression in premalignant and malignant oral lesions infected with human papillomavirus. J Histochem Cytochem 51(10):1291–1297PubMed
19.
Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich MC (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23(23):5357–5364 [Epub 2005 May 31]PubMedCrossRef
20.
Powell EL, Leoni LM, Canto MI, Forastiere AA, Iocobuzio-Donahue CA, Wang JS, Maitra A, Montgomery E (2005) Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications. Am J Surg Pathol 29(11):1497–1504PubMedCrossRef
21.
McCluggage WG, Jenkins D (2003) p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol 22(3):231–235PubMedCrossRef
22.
Vallmanya Llena FR, Laborda Rodríguez A, Lloreta Trull J, Cortadellas Angel R, Placer Santos J, Mas Gelabert A (2006) Immunohistochemical expression of p53, p21, p16, and cyclin D1 in superficial bladder cancer. A tissue microarray study. Actas Urol Esp 30(8):754–762PubMedCrossRef
23.
Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Löning T (2001) Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat 67(1):61–70PubMedCrossRef
24.
Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC (1995) Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 10(1):114–116PubMedCrossRef
25.
Miettinen M, Sobin LH, Lasota J (2005) Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with longterm follow-up. Am J Surg Pathol 29(1):52–68PubMedCrossRef
26.
Huang HY, Huang WW, Lin CN, Eng HL, Li SH, Li CF, Lu D, Yu SC, Hsiung CY (2006) Immunohistochemical expression of p16INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria. Ann Surg Oncol 13(12):1633–1644 [Epub 2006 Sep 30]PubMedCrossRef
27.
Kommoss S, du Bois A, Ridder R, Trunk MJ, Schmidt D, Pfisterer J, Kommoss F, the AGO-OVAR (2007) Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Br J Cancer 96(2):306–313
28.
29.
30.
Mittal K, Soslow R, McCluggage WG (2008) Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med 132(3):402–423
Metadata
Title
Ancillary p16INK4a adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study
Authors
Chung-Chin Yao
Lai-Fong Kok
Ming-Yung Lee
Po-Hui Wang
Tina S. Wu
Yeu-Sheng Tyan
Ya-Wen Cheng
Mei-Fen Kung
Chih-Ping Han
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Archives of Gynecology and Obstetrics / Issue 3/2009
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-008-0859-1

Other articles of this Issue 3/2009

Archives of Gynecology and Obstetrics 3/2009 Go to the issue

Case Report

Three isolated, large retroperitoneal leiomyomas

Case Report

Primary ovarian adenomyoma in a woman with endometrial polyp: a case report and review of the literature

Original Article

A randomized controlled trial comparing powdery sublingual misoprostol and sublingual misoprostol tablet for management of embryonic death or anembryonic pregnancy

Original Article

Surgical treatment of intractable postpartum hemorrhage and changing trends in modern obstetric perspective

Case Report

Devic’s neuromyelitis optica and pregnancy: distinction from multiple sclerosis is essential

Letter to the Editor

Three dimensional ultrasound diagnosis of caudal regression syndrome at 14 gestational weeks